Breyanzi’s Sales Increase While Abecma’s Remain Flat; How Will BMS Meet CAR-T Manufacturing Demand? Breyanzi On Track for EU Approval in 2L LBCL; BMS’s Q4 2021 Earnings Call Summary
On Friday, February 4, BMS held their Q4 2021 earnings call (press release / presentation) highlighting their manufacturing supply strategy for the anticipated increase in demand of Breyanzi (CD19 CAR-T) and Abecma (BCMA CAR-T). Below, Celltelligence provides insights on the potential challenges BMS may encounter expanding into earlier lines of therapy and additional geographies.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.